SCHEMBL3570410

SCHEMBL3570410

CCOC(=O)c1ccc(NC(=O)c2cc(OC)c3c(c2)N(S(=O)(=O)c2cccc(F)c2)CC3)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.54
SMN1; SMN2 Q16637 5/20 0.53
KMT2A Q03164 4/20 0.53
ALDH1A1 P00352 4/20 0.53
TP53 P04637 4/20 0.53
MEN1 O00255 3/20 0.53
LMNA P02545 3/20 0.53
MAPK1 P28482 2/20 0.53
USP2 O75604 1/20 0.53
GAA P10253 1/20 0.53
CPT1A P50416 6/20 0.49
CPT1B Q92523 5/20 0.49
CPT2 P23786 4/20 0.49
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3572320 0.91 CPT1A (0.54) MAPTSMN1; SMN2KMT2AALDH1A1LMNA
SCHEMBL3573791 0.90 MAPT (0.60) MAPTSMN1; SMN2KMT2AALDH1A1TP53
SCHEMBL3575184 0.89 CPT1A (0.59) MAPTSMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL30015196 0.89 CPT1A (0.59) MAPTSMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL3580222 0.87 MAPT (0.64) MAPTSMN1; SMN2KMT2AALDH1A1TP53
SCHEMBL3582338 0.84 RORC (0.63) MAPTSMN1; SMN2KMT2AALDH1A1TP53
SCHEMBL3574595 0.83 CPT2 (0.60) MAPTSMN1; SMN2KMT2AALDH1A1TP53
SCHEMBL3570225 0.83 CPT2 (0.56) MAPTSMN1; SMN2KMT2AALDH1A1CPT1A
SCHEMBL3580790 0.83 CPT1A (0.60) MAPTCPT1ACPT1BCPT2
SCHEMBL30015328 0.83 CPT1A (0.64) CPT1ACPT1BCPT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1926711-B1 NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE HOFFMANN LA ROCHE (CH) 2012-11-07 EP disclosed
US-7713996-B2 Indolyl derivatives which are L-CPT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2010-05-11 US disclosed
EP-1926711-A1 NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE F.HOFFMANN-LA ROCHE AG (CH) 2008-06-04 EP disclosed
WO-2007031429-A1 NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE F. HOFFMANN-LA ROCHE AG (CH) 2007-03-22 WO disclosed
US-20070060567-A1 Novel indolyl derivatives which are L-CPT1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060567-A1 Novel indolyl derivatives which are L-CPT1 inhibitors CPT1A, CPT1B, CPT2 MAPT 1807/4885SMN1; SMN2 4215/4885KMT2A 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.